12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

Dainippon's Sunovion Pharmaceuticals Canada Inc. subsidiary said Health Canada accepted for review an NDS for lurasidone to treat schizophrenia in adults. The application was submitted in June. Dainippon markets...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >